"Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares ( NASDAQ:LABU) offers the most aggressive way to capture that move. The fund's structure is simple but powerful: it delivers three times the daily return of the S&P Biotechnology Select Industry Index through derivatives and swaps. The fund has doubled over the past year as the underlying biotech sector gained momentum."
"That amplification works both ways. LABU has experienced significant volatility over longer timeframes, a reminder that leverage magnifies losses as dramatically as gains. But the sector is turning a corner. According to BioPharma Dive, biotech's market recovery accelerated in the second half of 2025 as regulatory uncertainty eased and dealmaking returned. For biotech investors, FDA approval decisions represent the single most important macro catalyst."
Direxion Daily S&P Biotech Bull 3X Shares (LABU) delivers three times the daily return of the S&P Biotechnology Select Industry Index using derivatives and swaps. The fund doubled over the past year as the biotech sector gained momentum, demonstrating how leverage amplifies returns when trends align. Leverage also magnifies losses, and LABU has experienced significant volatility over longer timeframes. Biotech's market recovery accelerated in the second half of 2025 as regulatory uncertainty eased and dealmaking resumed. FDA approval decisions act as primary macro catalysts, often sending approved stocks up 20% to 50% in a day. LABU holds over 200 biotech companies, so approvals can produce amplified portfolio moves. Monitor FDA calendars and PDUFA dates for key decision timing.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]